Imiquimod History

Scientists at 3M's biologic analysis crystalline imiquimod as allotment of a affairs to ascertain inhibitors of canker virus[disambiguation needed] archetype based on a accepted adenine derivative.:369–372 3M acquired the aboriginal FDA approval for it in 1997 as a analysis for alien animal and perianal warts beneath the brand, "Aldara". In 2004 3M acquired FDA approval to bazaar imiquimod as a analysis for crystalline basal corpuscle carcinoma.

In 2006, 3M awash its biologic business in the Americas to Graceway Pharmaceuticals, its European biologic business to Meda AB, and its biologic business in added territories to two clandestine disinterestedness firms.

Graceway declared defalcation in 2011 afterwards the cessation of the patents on imiquimod, and its assets, including the rights to imiquimod branding and approvals in the Americas, were purchased by Medicis Pharmaceutical.

As of 2015, imiquimod is all-encompassing and is accessible common beneath abounding brands.